Takeda Teams With Evozyne On Protein Design For Gene Therapy
Deal Snapshot: Building on a 2021 tie-up between Takeda and the Paragon start-up, Evozyne will seek novel protein sequences for inclusion in gene therapies for rare disease indications.
You may also be interested in...
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
Takeda will use Poseida’s non-viral delivery and gene-editing capabilities for six liver- and hematopoietic stem cell-targeted gene therapies. The agreement follows recent gene therapy tie-ups with Selecta and Genevant.
Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.